During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60246-elekta-sets-new-benchmark-for-cancer-treatment-launch-of-versa-hd-system
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
The Prostate Cancer Foundation (PCF) announces the launch of the “Step Up for Blue” Campaign for Prostate Cancer Awareness Month. The campaign honors the millions of men and their families touched by prostate cancer worldwide.
“Step Up for Blue” focuses on elevating critical issues to inspire, energize, and accelerate actions that lead to greater awareness, new therapies, and fewer deaths from prostate cancer. It will run through the duration of September.
To view the multimedia release go to:
http://www.multivu.com/players/English/7729253-pcf-step-up-for-blue-prostate-cancer/
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
It is estimated that almost 40 percent of men and women in the U.S. will be diagnosed with cancer sometime during their lifetime. Kommah, who was diagnosed at age 29, now has her health and her son, thanks to discoveries made at City of Hope, where scientists and doctors turn laboratory breakthroughs into treatments that defeat cancer.
Today, the nonprofit research and comprehensive cancer center near Los Angeles is rolling out a new initiative that builds on its legacy of discovery to let people know that City of Hope not only offers a uniquely patient-centric, integrated approach to care, but also with the help of donors and volunteers, it is pursuing research that will change the future of medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7665051-city-of-hope-miracle-science-soul-campaign/
In recognition of Pain Awareness Month (PAM), the Let’s Talk Pain Coalition today launched the Pain Medication Safety Series, an online video series featuring candid dialogues between health care professionals, people with pain and their caaregivers about the safe and appropriate use of pain therapies. A complete listing of episodes with descriptions is available at www.letstalkpain.com/painmedsafety.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/letstalkpain/45730/
The Department of Veterans Affairs (VA) is celebrating exceptional care for Veterans this week, May 2 – 6 as part of the nationally recognized Research Week. This year’s theme, “Discovery and Collaboration for Exceptional Health Care,” celebrates two crucial elements of VA research: dedicated follow-through on important research findings to optimize medical therapies for Veterans and others; and vital research and care collaborations between VA and academic institutions, other government agencies, and health-related industry.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/va/48428/
It may officially be Fall, but at ARIA Resort & Casino in Las Vegas the heat is still on. ARIA is one of the few Las Vegas Hotels with a year round pool and cabanas. Guests can enjoy water heated to a perfect 82 degrees whether it is 65 or 105 degrees outside. Cabanas with full food and beverage options as well as HD TVs, an iPod dock and even wifi are also available starting at $200 for up to 8 people.
Not in the mood to lounge by the pool? ARIA Resort & Casino offers one of the best spa experiences in Las Vegas as well. From traditional treatments to our innovative signature series therapies, there is literally something for everyone.
To view Multimedia News Release, go to http://www.multivu.com/players/English/57841-mgm-aria-resort-and-casino-las-vegas/
Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine today, with the goal to unlock genetic codes and develop drug therapies in real time to improve the outcome for thousands of young patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59399-phoenix-children-s-hospital-visionary-institute-of-molecular-medicine
http://www.getthehormonecure.com Dr.
Sara Gottfried refuses to accept the traditional medical thinking that
feeling cranky, asexual, tapped out, and sleep-deprived is just part of
being female and aging, and that prescription medication will fix all
problems. In The Hormone Cure, she combines natural therapies with
rigorous scientific testing to help women feel fully alive, especially
in the years prior to menopause. Using an informative questionnaire to
identify common symptoms of hormonal imbalance such as insomnia, low
sex drive, lack of energy, moodiness, hot flashes, and more; detailing
causes; and offering solutions in non-judgmental and thoughtful
language, Dr. Gottfried provides a novel plan based on solid scientific
research. She believes you don't find a cure at the bottom of a pill
bottle.
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
